Navigation Links
Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone

fludarabine and rituximab (F-R) in the treatment of patients who have received at least one prior treatment for NHL. The trial is expected to enroll 300 patients.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to have the same cardiotoxicity profile in humans as demonstrated in preclinical studies or to prove safe and effective for treatment of non-Hodgkin's lymphoma or other cancer, determinations by regulatory, patent and administrative governmental authorities,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
(Date:10/3/2008)...to Study B-Raf Kinase Inhibitors for Cancer Treatm... 3 /-,Eli Lilly and Company...ceuticals, LLC today announced that the two compan...e licensing agreement related to,Deciphera,s precl...y of,potential oncology therapeutics., The collab...
(Date:10/2/2008)...l Compare the Results of Rosetta Genomics, microRN...tiates Squamous From non Squamous non Small C...A Test Based on the miRview(TM) Technology First A...rsity,s High Complexity Molecular Pathology Lab ...a Genomics is Expecting to Launch miRview(TM) Squa...
(Date:10/2/2008)...er 2 /- Pharmaleads has obtained from...ation to perform a single,ascending dose Phase I s...nt of neuropathic pain., Neuropathic pain is a ma...alence in the world,s population of up to 6%, acco... such as shingles, herpes, diabetes,antiviral or ...
(Date:10/2/2008)...ctober 2 /- Athera Biotechnologies AB...at they have entered into a,collaboration to disco...evention or treatment of cardiovascular inflammato...t publication of work by Athera,scientific founder...inska,Institutet. The research links naturally occ...
Breaking Medicine Technology:Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 2Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Leading worldwide cause of cardiovascular disease may be modified by diet 23462 1Leading worldwide cause of cardiovascular disease may be modified by diet 23462 2Can tomatoes carry the cure for Alzheimers 3F 3940 1Can tomatoes carry the cure for Alzheimers 3F 3940 2Self moisturizing contact lenses naturally 3938 1Self moisturizing contact lenses naturally 3938 2Crop management 3A How small do we go 3F 3936 1
...IRE)--Jun 20, 2007 - Materia, Inc., a,catalyst tec...its,metathesis platform to Eisai Co., Ltd., a lead...ug discovery and development.,The non-exclusive li...op, and patent pharmaceutical compounds and relate...ciated intellectual property., Metathesis catalyst...
...Jun 20, 2007 - Today, President Bush,Signed An Exe... To,Research On Pluripotent Stem Cells. Scientists...kill to pursue the potential benefits,of pluripote...e the,potential to develop into nearly all the cel...ing human life in the process. By,expanding suppor...
Other Medicine Technology:Materia Licenses Metathesis Catalyst Platform to Eisai 2Fact Sheet: Advancing Stem Cell Research While Respecting Moral,Boundaries 2Fact Sheet: Advancing Stem Cell Research While Respecting Moral,Boundaries 3
(Date:10/6/2008)...t. 6 /PRNewswire/ -- Developed in collaboration wi...ades, CA is introducing,Revolutionary Breast Surfa...c Surgery office of Dr. Steve Laverson this week i...he first of its kind, and is based on,breakthrough...with,innovative proprietary software. The XS-300(T...
(Date:10/6/2008)...ct. 6 /PRNewswire/ -- The organizers of Informex a...e on Global Sourcing for the,Pharmaceutical Indust...inceton Marriott in New Jersey USA., The conferen... the,Global Sourcing Council, and boasts an unpara...e likes of Johnson & Johnson, Bristol Myers Squibb...
(Date:10/6/2008)... LegalView recently posted detailed inform...he potentially serious side effects caused by the ... the drug,s potential side effects are the develop... for young adult and child patients. , ...- LegalView, the number one resource for everythin...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
... Institute of Technology (MIT) has found out why r...rm, and squeeze through tiny blood vessels during ...ucing parasite Plasmodium falciparum. The resear...te protein called RESA (ring-infected erythrocyte ...
...apital on Saturday. The Nigah Queer Fest will s... many international directors. The films will be f...esentation. The aim of the programme is to give v...country where Section 377 of the Indian Penal Code...
...ing parental bliss to the fullest. In a recent i..., Pitt poured his heart out about the delight and ... scan yet? They're mind-blowing. Get ready to chan...ers. I love being a dad - it's the best thing that...
...ollowing revelations that a common preservative fo...x has the ability to switch off vital parts of DN...parts of DNA are disabled, as it were, it could ev...and degenerative diseases such as Parkinson's. ...
Other Medicine News:Health News:Why Malaria Parasite Affects Red Blood Cells Deformability Revealed 2Health News:Gay Film Festival Begins in Delhi 2Health News:Soft Drink Additive Could Cause Cell Damage 2Health News:Soft Drink Additive Could Cause Cell Damage 3
...s a wide range of innovative features, including H...Control (U.S. Patent #4,684,227). Stereopsis is ma...unique Diffuser aperture absorbs only 30% of the i...ifying difficult examinations. A newly incorporate...
3-wire patient cable and 4 metal chest electrodes on the back of the unit. 3-step procedure enabling a patient to easily self-record an 8 or 12 lead ECG through a simple change of the devices positio
...IMPACs comprehensive information system designed s...ies to integrate and streamline their diagnostic, ...ntuitive software solution. Thousands of laborator...ve proven PowerPaths unique "case-centric model to...
The Digital-Photo Adapter DC 01 provides exclusively designed optics for the BQ 900 Slit Lamp technology. In combination with a state-of-the-art digital camera this is the best choice for quality, fl
Medicine Products: